STAT3 inhibition as a therapeutic strategy for leukemia

Rubashruti Kanna, Gaurav Choudhary, Nandini Ramachandra, Ulrich G. Steidl, Amit K. Verma, Aditi Shastri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Leukemia is characterized by selective overgrowth of malignant hematopoietic stem cells (HSC’s) that interfere with HSC differentiation. Cytoreductive chemotherapy can kill rapidly dividing cancerous cells but cannot eradicate the malignant HSC pool leading to relapses. Leukemic stem cells have several dysregulated pathways and the Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) pathway are prominent among them. STAT3 is an important transcription factor that regulates cell growth, proliferation, and inhibits apoptosis. High STAT3 expression in leukemia has been associated with an increased risk for relapse and decreased overall survival. Multiple strategies for interfering with STAT3 activity in leukemic cells include inhibition of STAT3 phosphorylation, interfering with STAT3 interactions, preventing nuclear transfer, inhibiting transcription and causing interference in STAT: DNA binding. A better understanding of key interactions and upstream mediators of STAT3 activity will help facilitate the development of effective cancer therapies and may result in durable remissions.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Nov 23 2017

Fingerprint

Hematopoietic Stem Cells
Leukemia
Transducers
Janus Kinases
Recurrence
Cell Differentiation
Transcription Factors
Stem Cells
Therapeutics
Phosphorylation
Cell Proliferation
Apoptosis
Drug Therapy
DNA
Growth
Neoplasms

Keywords

  • Leukemia
  • signal transduction
  • transcription factor changes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

STAT3 inhibition as a therapeutic strategy for leukemia. / Kanna, Rubashruti; Choudhary, Gaurav; Ramachandra, Nandini; Steidl, Ulrich G.; Verma, Amit K.; Shastri, Aditi.

In: Leukemia and Lymphoma, 23.11.2017, p. 1-7.

Research output: Contribution to journalArticle

Kanna, Rubashruti ; Choudhary, Gaurav ; Ramachandra, Nandini ; Steidl, Ulrich G. ; Verma, Amit K. ; Shastri, Aditi. / STAT3 inhibition as a therapeutic strategy for leukemia. In: Leukemia and Lymphoma. 2017 ; pp. 1-7.
@article{0f0270182911485e8a9a875c15fdca31,
title = "STAT3 inhibition as a therapeutic strategy for leukemia",
abstract = "Leukemia is characterized by selective overgrowth of malignant hematopoietic stem cells (HSC’s) that interfere with HSC differentiation. Cytoreductive chemotherapy can kill rapidly dividing cancerous cells but cannot eradicate the malignant HSC pool leading to relapses. Leukemic stem cells have several dysregulated pathways and the Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) pathway are prominent among them. STAT3 is an important transcription factor that regulates cell growth, proliferation, and inhibits apoptosis. High STAT3 expression in leukemia has been associated with an increased risk for relapse and decreased overall survival. Multiple strategies for interfering with STAT3 activity in leukemic cells include inhibition of STAT3 phosphorylation, interfering with STAT3 interactions, preventing nuclear transfer, inhibiting transcription and causing interference in STAT: DNA binding. A better understanding of key interactions and upstream mediators of STAT3 activity will help facilitate the development of effective cancer therapies and may result in durable remissions.",
keywords = "Leukemia, signal transduction, transcription factor changes",
author = "Rubashruti Kanna and Gaurav Choudhary and Nandini Ramachandra and Steidl, {Ulrich G.} and Verma, {Amit K.} and Aditi Shastri",
year = "2017",
month = "11",
day = "23",
doi = "10.1080/10428194.2017.1397668",
language = "English (US)",
pages = "1--7",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - STAT3 inhibition as a therapeutic strategy for leukemia

AU - Kanna, Rubashruti

AU - Choudhary, Gaurav

AU - Ramachandra, Nandini

AU - Steidl, Ulrich G.

AU - Verma, Amit K.

AU - Shastri, Aditi

PY - 2017/11/23

Y1 - 2017/11/23

N2 - Leukemia is characterized by selective overgrowth of malignant hematopoietic stem cells (HSC’s) that interfere with HSC differentiation. Cytoreductive chemotherapy can kill rapidly dividing cancerous cells but cannot eradicate the malignant HSC pool leading to relapses. Leukemic stem cells have several dysregulated pathways and the Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) pathway are prominent among them. STAT3 is an important transcription factor that regulates cell growth, proliferation, and inhibits apoptosis. High STAT3 expression in leukemia has been associated with an increased risk for relapse and decreased overall survival. Multiple strategies for interfering with STAT3 activity in leukemic cells include inhibition of STAT3 phosphorylation, interfering with STAT3 interactions, preventing nuclear transfer, inhibiting transcription and causing interference in STAT: DNA binding. A better understanding of key interactions and upstream mediators of STAT3 activity will help facilitate the development of effective cancer therapies and may result in durable remissions.

AB - Leukemia is characterized by selective overgrowth of malignant hematopoietic stem cells (HSC’s) that interfere with HSC differentiation. Cytoreductive chemotherapy can kill rapidly dividing cancerous cells but cannot eradicate the malignant HSC pool leading to relapses. Leukemic stem cells have several dysregulated pathways and the Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) pathway are prominent among them. STAT3 is an important transcription factor that regulates cell growth, proliferation, and inhibits apoptosis. High STAT3 expression in leukemia has been associated with an increased risk for relapse and decreased overall survival. Multiple strategies for interfering with STAT3 activity in leukemic cells include inhibition of STAT3 phosphorylation, interfering with STAT3 interactions, preventing nuclear transfer, inhibiting transcription and causing interference in STAT: DNA binding. A better understanding of key interactions and upstream mediators of STAT3 activity will help facilitate the development of effective cancer therapies and may result in durable remissions.

KW - Leukemia

KW - signal transduction

KW - transcription factor changes

UR - http://www.scopus.com/inward/record.url?scp=85034654890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034654890&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1397668

DO - 10.1080/10428194.2017.1397668

M3 - Article

C2 - 29164994

AN - SCOPUS:85034654890

SP - 1

EP - 7

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -